{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T05:23:56Z","timestamp":1738733036391,"version":"3.37.0"},"reference-count":48,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2008,11,25]],"date-time":"2008-11-25T00:00:00Z","timestamp":1227571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Interven Cardiology"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:p><jats:italic>Fundamentally, acute coronary syndromes are platelet\u2010centric diseases, resulting from platelet\u2010rich thrombi that develop at the site of vessel wall injury. In addition to aggregation, platelets modulate a plethora of other important pathophysiologic processes, including inflammation and coagulation. Therefore, a primary goal of therapy in the acute setting should be treatment with agents that provide predictable and superior platelet inhibition to prevent further ischemic events that develop from unchecked high platelet reactivity. Translational research studies of patients undergoing percutaneous revascularization have clearly demonstrated that adverse thrombotic outcomes are associated with high platelet reactivity and the latter is now emerging as a potent measurable cardiovascular risk factor. The intensity of antithrombotic therapy is influenced by patient risk. In the highest risk patients with elevated cardiac biomarkers indicative of myonecrosis, current guidelines support the use of early therapy with glycoprotein IIb\/IIIa inhibition, aspirin, and clopidogrel.<\/jats:italic><\/jats:p>","DOI":"10.1111\/j.1540-8183.2008.00408.x","type":"journal-article","created":{"date-parts":[[2008,11,25]],"date-time":"2008-11-25T14:28:16Z","timestamp":1227623296000},"source":"Crossref","is-referenced-by-count":8,"title":["The Rationale for and Comparisons of Different Antiplatelet Treatments in Acute Coronary Syndrome"],"prefix":"10.1111","volume":"21","author":[{"given":"PAUL A.","family":"GURBEL","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"UDAYA S.","family":"TANTRY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,11,25]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-027698"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.2217\/14796678.2.3.343"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.07.041"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2001.3237"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.19.2323"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.14.1799"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.tb03240.x"},{"key":"e_1_2_7_9_2","first-page":"196A","article-title":"Transition to an unstable coronary syndrome is marked by hypercoagulability, platelet activation, heightened platelet reactivity, and inflammation: Results of the Thrombotic RIsk Progression (TRIP) study","volume":"49","author":"Tantry US","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1586\/14779072.2.4.535"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000130846.46168.03"},{"key":"e_1_2_7_12_2","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1161\/circ.116.suppl_16.II_785-b","article-title":"The prediction of ischemic events after percutaneous coronary intervention by platelet reactivity to adenosine diphosphate: First evidence for an oral antiplatelet therapeutic target determined by an ex vivo test of platelet function","volume":"116","author":"Gurbel PA","year":"2007","journal-title":"Circulation"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000157138.02645.11"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01751.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.051"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.10497"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.07.056"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.01.094"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.10.1206"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.10.002"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.675587"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.2337\/db07-0707"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.05.041"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.06.013"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8183.2006.00181.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050522"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.10.1224"},{"key":"e_1_2_7_29_2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.20452\/pamw.130","article-title":"The role of clopidogrel in cardiovascular diseases","volume":"117","author":"Gurbel PA","year":"2007","journal-title":"Pol Arch Med Wewn"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612033453884"},{"key":"e_1_2_7_32_2","unstructured":"MoliternoDJ JenningsL BeckerRC et al. for TRA\u2010PCI Investigators.Results of a multinational randomized double\u2010blind placebo\u2010controlled study of a novel thrombin receptor antagonist SCH 530348 in percutaneous coronary intervention. Presented at American College of Cardiology Meetings 2007."},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11086-3"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(03)00437-X"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.23.10624"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00805.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10452-9"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000018123.02672.C7"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.19.2405"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.08.060"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.13.joc60034"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm562"},{"key":"e_1_2_7_43_2","unstructured":"KastratiA NeumannFJ MehilliJ et al.Bivalirudin versus unfractionated heparin in biomarker negative patients with stable and unstable angina undergoing PCI; ISAR\u2010REACT 3 (Intracoronary Stenting and Antithrombotic Regimen\u2010Rapid Early Action for Coronary Treatment 3) trial. Presented at American College of Cardiology 2008 Scientific Sessions\/i2 Summit\u2010SCAI Annual Meeting Chicago 2008."},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.12.084"},{"key":"e_1_2_7_45_2","unstructured":"GurbelPA BlidenKP KreutzRP et al.Superior effect of eptifibatide added to clopidogrel on biomarker expression detected by fluorokine multi\u2010analyte profiling in patients undergoing elective PCI. Presented at International Society of Thrombosis and Hemostasis Society Meeting2007 Geneva .P\u2010S\u2010343."},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.7.853"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062437"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60450-4"},{"key":"e_1_2_7_49_2","first-page":"2364","article-title":"Bivalirudin with and without eptifibatide for elective stenting: A pharmacodynamic study of platelet reactivity in relation to the occurrence of periprocedural myocardial infarction","volume":"116","author":"Gurbel PA","year":"2007","journal-title":"Circulation"}],"container-title":["Journal of Interventional Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1540-8183.2008.00408.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1540-8183.2008.00408.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T16:46:15Z","timestamp":1738687575000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1540-8183.2008.00408.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,25]]},"references-count":48,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1111\/j.1540-8183.2008.00408.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1540-8183.2008.00408.x","archive":["Portico"],"relation":{},"ISSN":["0896-4327","1540-8183"],"issn-type":[{"type":"print","value":"0896-4327"},{"type":"electronic","value":"1540-8183"}],"subject":[],"published":{"date-parts":[[2008,11,25]]}}}